DOCSLIB.ORG

CNS SPECTRUMS CME Review Article Keeping up with the Clinical Advances: Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CNS SPECTRUMS CME Review Article Keeping up with the Clinical Advances: Schizophrenia CNS SPECTRUMS CME Review Article Keeping up with the clinical advances: schizophrenia This activity is provided by the Neuroscience Education Institute. Additionally provided by the American Society for the Advancement of Pharmacotherapy. Downloaded from https://www.cambridge.org/core. IP address: 170.106.33.42, on 27 Sep 2021 at 16:43:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S109285291900124X CME Information Released: July 25, 2019 Peer Review CME credit expires: May 15, 2022 This content has been peer reviewed by an MD specializ- ing in psychiatry to ensure the scientific accuracy and Learning Objectives medical relevance of information presented and its inde- After completing this activity, you should be better able to: pendence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this • Differentiate the mechanisms of action of new and CME activity. emerging antipsychotics • Evaluate the latest clinical data on new and emerg- Disclosures ing antipsychotics All individuals in a position to influence or control con- tent are required to disclose financial relationships of any Accreditation and Credit Designation amount with any entity producing, marketing, re-selling, Statements or distributing health care goods or services consumed The Neuroscience Education Institute (NEI) is accred- by, or used on, patients. Although potential conflicts of ited by the Accreditation Council for Continuing interest are identified and resolved prior to the activity Medical Education (ACCME) to provide continuing being presented, it remains for the participant to deter- medical education for physicians. mine whether outside interests reflect a possible bias in NEI designates this enduring material for a maximum either the exposition or the conclusions presented. of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of Authors their participation in the activity. A posttest score of Amanda Krogmann, BSc, is affiliated with Charité 70% or higher is required to earn CME credits. Universitätsmedizin, Department of Child and Adolescent The American Society for the Advancement of Psychiatry in Berlin, Germany. Ms Krogmann has no finan- Pharmacotherapy (ASAP), Division 55 of the American cial relationships to disclose. Psychological Association, is approved by the American Luisa Peters, BSc, is affiliated with Charité Psychological Association to sponsor continuing educa- Universitätsmedizin, Department of Child and Adolescent tion for psychologists. ASAP maintains responsibility Psychiatry in Berlin, Germany. Ms Peters has no financial for this program and its content. relationships to disclose. The American Society for the Advancement of Laura von Hardenberg, MPhil, is affiliated with Pharmacotherapy designates this program for 1.5 CE Charité Universitätsmedizin, Department of Child and credits for psychologists. Adolescent Psychiatry in Berlin, Germany. Ms von Nurses and Physician Assistants: for all of your Hardenberg has no financial relationships to disclose. CE requirements for recertification, the ANCC and Katja Bödeker, PhD, is affiliated with Charité NCCPA will accept AMA PRA Category 1 Credits™ from Universitätsmedizin, Department of Child and Adolescent organizations accredited by the ACCME. The content of Psychiatry in Berlin, Germany. Dr. Bödeker has no financial this activity pertains to pharmacology and is worth 1.5 relationships to disclose. continuing education hours of pharmacotherapeutics. Viktor B. Nöhles, MA, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Optional Posttest and CME Credit Instructions Psychiatry in Berlin, Germany. Mr. Nöhles has no financial 1 Read the article relationships to disclose. 2 Complete the posttest, available only online at Christoph U. Correll, MD, is affiliated with Charité www.neiglobal.com/CME (under “CNS Universitätsmedizin, Department of Child and Adolescent Spectrums”) Psychiatry in Berlin, Germany; the Zucker Hillside 3 Print your certificate (passing score = 70% or Hospital, Psychiatry Research, Northwell Health in Glen higher) Oaks, New York, USA; and Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Questions? call 888–535–5600, or email Molecular Medicine in Hempstead, New York, USA. [email protected] Dr. Correll has been a consultant/advisor to or has received Downloaded from https://www.cambridge.org/core. IP address: 170.106.33.42, on 27 Sep 2021 at 16:43:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S109285291900124X honoraria from: Alkermes, Allergan, Angelini, Boehringer- The Content Editor, an NEI Peer Reviewer, and the Ingelheim, Gedeon Richter, Gerson Lehrman Group, Planning Committee have no financial relationships Indivior, IntraCellular Therapies, Janssen/J&J, LB to disclose. Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Disclosure of Off-Label Use Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, This educational activity may include discussion of unla- Takeda, and Teva. He has provided expert testimony for beled and/or investigational uses of agents that are not Bristol-Myers Squibb, Janssen, and Otsuka. He served on currently labeled for such use by the FDA. Please consult a Data Safety Monitoring Board for Boehringer- the product prescribing information for full disclosure of Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He labeled uses. received royalties from UpToDate and grant support from Janssen and Takeda, and is also a shareholder of LB Pharma. Cultural and Linguistic Competency No writing assistance was utilized in the production of this article. A variety of resources addressing cultural and linguistic competency can be found at this link: www.neiglobal. CNS Spectrums Peer Review com/go/cmeregs All CME articles are peer reviewed in accordance with the strict standards of CNS Spectrums and in accordance with Providers requirements and recommendations of the International This activity is provided by NEI. Additionally provided by Committee of Medical Journal Editors. The Editorial pol- the ASAP. icies of the journal CNS Spectrums and peer review of all articles that appear in the journal is managed independ- Support ently by Cambridge University Press and no financial relationship exists between the CME provider and This activity is supported by an unrestricted educational Cambridge for this service. grant from Indivior. Downloaded from https://www.cambridge.org/core. IP address: 170.106.33.42, on 27 Sep 2021 at 16:43:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S109285291900124X CNS Spectrums (2019), 24,41–68. © The Author(s) 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which per- mits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. doi:10.1017/S109285291900124X REVIEW ARTICLE Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities Amanda Krogmann,1,† Luisa Peters,1,† Laura von Hardenberg,1 Katja Bödeker,1 Viktor B. Nöhles,1 and Christoph U. Correll1,2,3* 1 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany 2 Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA 3 Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation anti- psychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non- adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated recep- tor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/ loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable
Load more

Recommended publications
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    A synbiotic mixture augmented the efficacy of doxepin, venlafaxine, and fluvoxamine in mice model of depression Azadeh Mesripour1, Andiya Meshkati1, Valiolah Hajhashemi2 1Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. 2‐ Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. ABSTRACT Objective: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals, may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicineproof in order to augment the efficacy of therapeutic doses of antidepressant drugs seems to be very important. Therefore the effect of adding a synbiotic cocktail in drinking water was assessed in mice model of despair following administrating three antidepressant drugs belonging to different classes. Methods: The marble burring test (MBT), and forced swimming test (FST) were used as animal model of obsessive behavior and despair. The synbiotic cocktail was administered in mice drinking water (6.25×106 CFU) for 14 days and the tests were performed on the days 7 and 14 thirty minutes after injecting the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg). Results: After 7 days of the synbiotic ingestion immobility time decreased in FST for doxepin (92 sec ± 5.5) and venlafaxine (17.3 sec ± 2.5) compared to their control group (drinking water) but fluvoxamine could decrease immobility time after 14 days of ingesting the synbiotic (70 sec ± 7.5).
    [Show full text]
  • Clinical Expertise and Patient Focus November, 2019
    Clinical Expertise and Patient Focus November, 2019 1 Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva whether any of our therapeutic products will advance further in the Neurosciences which are subject to the safe harbor provisions of the clinical trials process and whether and when, if at all, they will receive Private Securities Litigation Reform Act of 1995, as amended. Forward- final approval from the U.S. Food and Drug Administration or looking statements are statements that are not historical facts, reflect equivalent foreign regulatory agencies and for which indications; management’s expectations as of the date of this presentation, and whether the results of future clinical trials of roluperidone, seltorexant, involve certain risks and uncertainties. Forward-looking statements MIN-117 and MIN-301, if any, will be consistent with the results of past include, but are not limited to: the benefits, efficacy and safety of our clinical trials; whether roluperidone, seltorexant, MIN-117 and MIN-301 new formulations; the potential of the diagnosis and treatment of will be successfully marketed if approved; whether our therapeutic negative symptoms of schizophrenia and other diseases; whether product discovery and development efforts will be successful; our studies performed on analogs or backups of our compounds are a good ability to achieve the results contemplated by our co-development predictor of the clinical efficacy of our compounds; statements with agreements; the strength
    [Show full text]
  • Minerva Neurosciences Announces the Results
    Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension May 11, 2021 Key results Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) observed over one year (12-week double-blind and 40-week open-label periods) in patients receiving both 64 mg and 32 mg doses Continuous improvement in Personal and Social Performance (PSP) total score over one year, suggesting improvement in patients’ everyday life functioning Favorable safety profile with few serious adverse events and no evidence of somnolence, extrapyramidal side effects or weight gain Limited number of relapses observed over one year Results provide additional support for continued development of roluperidone and submission of NDA following completion of bioequivalence study and other work to address FDA comments from the Company’s Type C meeting held on November 10, 2020 Findings to be discussed during Q1 2021 conference call and webcast on May 12, 2021, at 8:30 a.m. WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from the 40-week open-label extension (OLE) of its phase 3 trial of roluperidone for the treatment of negative symptoms (NS) of schizophrenia. The OLE followed the 12-week double-blind, placebo-controlled portion of this trial. During the OLE, both investigators and patients were blinded to the roluperidone dose received (see “About the trial” below).
    [Show full text]
  • Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2)
    ORIGINAL RESEARCH published: 09 November 2020 doi: 10.3389/fnbeh.2020.578443 Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse 1 1† 2 1 Edited by: Niclas König , Zisis Bimpisidis , Sylvie Dumas and Åsa Wallén-Mackenzie * Nuno Sousa, 1Unit of Comparative Physiology, Department of Organismal Biology, Uppsala University, Uppsala, Sweden, 2Oramacell, University of Minho, Portugal Paris, France Reviewed by: Ali Salahpour, University of Toronto, Canada The vesicular monoamine transporter 2 (VMAT2) has a range of functions in the Louis-Eric Trudeau, central nervous system, from sequestering toxins to providing conditions for the quantal Université de Montréal, Canada release of monoaminergic neurotransmitters. Monoamine signaling regulates diverse *Correspondence: functions from arousal to mood, movement, and motivation, and dysregulation of Åsa Wallén-Mackenzie [email protected] VMAT2 function is implicated in various neuropsychiatric diseases. While all monoamine- releasing neurons express the Vmat2 gene, only a subset is positive for the calcium- †Present address: Zisis Bimpisidis, binding protein Calbindin 2 (Calb2; aka Calretinin, 29 kDa Calbindin). We recently Department of Neuroscience and showed that about half of the dopamine neurons in the mouse midbrain are positive Brain Technologies, Istitito Italiano di Tecnologia, Genova, Italy for Calb2 and that Calb2 is an early developmental marker of
    [Show full text]
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    Turk J Pharm Sci 2020;17(3):293-298 DOI: 10.4274/tjps.galenos.2019.94210 ORIGINAL ARTICLE A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression Sinbiyotik Karışım, Fare Depresyon Modelinde Doksepin, Venlafaksin ve Fluvoksaminin Etkinliğini Artırdı Azadeh MESRIPOUR1*, Andiya MESHKATI1, Valiollah HAJHASHEMI2 1Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Toxicology, Isfahan, Iran 2Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Isfahan Pharmaceutical Sciences Research Center, Isfahan, Iran ABSTRACT Objectives: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicine in order to augment the efficacy of therapeutic doses of antidepressant drugs appears to be very important. Therefore, the effect of adding a synbiotic mixture to drinking water was assessed in a mouse model of depression following the administration of three antidepressant drugs belonging to different classes. Materials and Methods: The marble burying test (MBT) and forced swimming test (FST) were used as animal models of obsessive behavior and despair. The synbiotic mixture was administered to the mice’s drinking water (6.25x106 CFU) for 14 days and the tests were performed 30 min after the injection of the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg) on days 7 and 14. Results: After 7 days of ingestion of the synbiotic mixture, immobility time decreased in the FST for doxepin (92±5.5 s) and venlafaxine (17.3±2.5 s) compared to the control group (drinking water), but fluvoxamine decreased immobility time after 14 days of ingestion of the synbiotic mixture (70±7.5 s).
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • “Indagandis Sedibus Et Causis Morborum” Potential Conflicts of Interest (January 2016 to Present)
    Siegfried KASPER Emeritus Chair Department of Psychiatry and Psychotherapy Brain Research Institute “Indagandis sedibus et causis morborum” www.mghcme.org Potential Conflicts of Interest (January 2016 to Present) Dr. Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Janssen, Lundbeck, and Schwabe; and he has served on speakers bureaus for Angelini, Krka Pharma, Lundbeck, Neuraxpharma, Schwabe, Servier and Sun Pharma. www.mghcme.org Schizophrenias Are Multifactorial Diseases Rujescu, 2019 www.mghcme.org Schizophrenia: Course of illness Millan et al., Nat Rev Drug Discov 2016 www.mghcme.org Schizophrenia: Impact of Symptomatology Work Quality of Social life Function Positive Symptoms Negative Symptoms o Hallucination o Blunted affect o Delusion o Anhedonia o Catatonia o Sozcial withdrawn o … o Etc… Number of Side Relapses Effects Cognitive Symptoms Affective Symptoms o Working Memory o Anxiety and Stress o Processing Speed o Depression Mortality Attention Suicidality Life o o Expectancy o … o … Response Remission Recovery www.mghcme.org Selecting Suitable Treatments for Schizophrenia Can Pose a Dilemma for Psychiatrists In selecting treatments for schizophrenia, physicians consider variables related to the:1,2 Patient Illness Medication Environment An ‘ideal’ medication is one that can:2 • Treat psychosis • Lead to symptom resolution The dilemma for physicians: • Lead to remission providing effective treatment while 3 • Overcome treatment resistance avoiding side effects • Prevent relapse • Have a benign side-effect profile The need to assess how side effects • Alleviate anxiety and depression interact with the patient’s life4-6 1. Kane et al. Dialogues Clin Neurosci 2010;12(3):345–357 2.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Roluperidone (MIN-101)
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Roluperidone (MIN-101) Evidence Summary The evidence for roluperidone is limited to a single randomized controlled trial in schizophrenia patients. Roluperidone may interact with medications that inhibit CYP2D6. Neuroprotective Benefit: Roluperidone improved several cognitive scores in schizophrenia patients, but it is not known whether it would benefit age-related cognitive decline or dementia. Aging and related health concerns: No studies have tested roluperidone for age-related conditions. Safety: Common adverse events with roluperidone included headache and anxiety based on a study in schizophrenia patients, though a few serious adverse events were also observed (vomiting, syncope, bradycardia). May interact with CYP2D6 inhibitors. 1 Availability: Not available; in Dose: The clinical trial in Chemical formula: C22H23FN2O2 clinical trials schizophrenia patients tested two MW: 366.4 oral doses: 32 mg/day
    [Show full text]
  • Negative Symptoms of Schizophrenia
    NEGATIVE SYMPTOMS OF SCHIZOPHRENIA March 22, 2018 Confidential & Proprietary Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this presentation, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to: the benefits, efficacy and safety of our new formulations; the potential of the diagnosis and treatment of negative symptoms of schizophrenia; statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; our expectations regarding approval for our products by the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; estimates regarding the market potential for our products; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether
    [Show full text]
  • Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
    pharmaceutics Review Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics Francisco José Toja-Camba 1,2,† , Nerea Gesto-Antelo 3,†, Olalla Maroñas 3,†, Eduardo Echarri Arrieta 4, Irene Zarra-Ferro 2,4, Miguel González-Barcia 2,4 , Enrique Bandín-Vilar 2,4 , Victor Mangas Sanjuan 2,5,6 , Fernando Facal 7,8 , Manuel Arrojo Romero 7, Angel Carracedo 3,9,10,* , Cristina Mondelo-García 2,4,* and Anxo Fernández-Ferreiro 2,4,* 1 Pharmacy Department, University Clinical Hospital of Ourense (SERGAS), Ramón Puga 52, 32005 Ourense, Spain; [email protected] 2 Clinical Pharmacology Group, Institute of Health Research (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain; [email protected] (I.Z.-F.); [email protected] (M.G.-B.); [email protected] (E.B.-V.); [email protected] (V.M.S.) 3 Genomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] (N.G.-A.); [email protected] (O.M.) 4 Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Citation: Toja-Camba, F.J.; 15706 Santiago de Compostela, Spain; [email protected] Gesto-Antelo, N.; Maroñas, O.; 5 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Echarri Arrieta, E.; Zarra-Ferro, I.; 46100 Valencia, Spain González-Barcia, M.; Bandín-Vilar, E.; 6 Interuniversity Research Institute for Molecular Recognition and Technological Development,
    [Show full text]
  • Differential Modulation of the Central and Peripheral Monoaminergic Neurochemicals by Deprenyl in Zebrafish Larvae
    toxics Article Differential Modulation of the Central and Peripheral Monoaminergic Neurochemicals by Deprenyl in Zebrafish Larvae Marina Bellot 1, Helena Bartolomé 1, Melissa Faria 2, Cristian Gómez-Canela 1,* and Demetrio Raldúa 2,* 1 Department of Analytical Chemistry and Applied (Chromatography Section), School of Engineering, Institut Químic de Sarrià-Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain; [email protected] (M.B.); [email protected] (H.B.) 2 Institute for Environmental Assessment and Water Research (IDAEA-CSIC), Jordi Girona, 18, 08034 Barcelona, Spain; [email protected] * Correspondence: [email protected] (C.G.-C.); [email protected] (D.R.); Tel.: +34-93-2672343 (C.G.-C.); +34-93-4006138 (D.R.) Abstract: Zebrafish embryos and larvae are vertebrate models increasingly used in translational neuroscience research. Behavioral impairment induced by the exposure to neuroactive or neurotoxic compounds is commonly linked to changes in modulatory neurotransmitters in the brain. Although different analytical methods for determining monoaminergic neurochemicals in zebrafish larvae have been developed, these methods have been used only on whole larvae, as the dissection of the brain of hundreds of larvae is not feasible. This raises a key question: Are the changes in the monoaminergic profile of the whole larvae predictive of the changes in the brain? In this study, the levels of ten monoaminergic neurotransmitters were determined in the head, trunk, and the whole body of zebrafish larvae in a control group and in those treated for 24 h with 5 M deprenyl, Citation: Bellot, M.; Bartolomé, H.; a prototypic monoamine-oxidase B inhibitor, eight days post-fertilization.
    [Show full text]